<DOC>
	<DOCNO>NCT00725348</DOCNO>
	<brief_summary>This study new oral drug use treatment psoriasis . All subject get active medication , placebo arm .</brief_summary>
	<brief_title>An Open-Label , Multi-Center Trial Treatment Subjects With Moderate Severe Plaque Type Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>R 115866</mesh_term>
	<criteria>Male female nonchildbearing potential ( least 2 year postmenopausal undergone successful surgical sterilization least 1 year inclusion ) Presence moderate severe plaque psoriasis PASI least 5 Pustular , guttate nonplaque form psoriasis psoriatic arthritis Significant coexisting hepatic , renal , bone marrow disease , hyperlipidemia , chronic pancreatitis , osteoporosis , history indicate adrenal cortex dysfunction serious disease ( include cancer subject know HIV positive ) History heart failure , myocardial infarction within past six month , cardiac arrhythmia , treatment heart disorder Clinically significant abnormal ECGintervals morphology ECG ; QT QTc &gt; 470 m female &gt; 450 m male Use vitamin A ( &gt; 1000 Âµg/day ) , phenytoin , carbamazepine , warfarin , rifampicin , tetracycline , ketoconazole , itraconazole , astemizole , terfenadine , cisapride , antipsychotic , antidepressant , lithium , antimalarial , alphablocking drug , angiotensinconverting enzyme inhibitor , cyclosporin A , glucocorticosteroids nonsteroidal antiinflammatory drug , nonpotassiumsparing diuretic Previous use systemic immunomodulatory therapy ( biologicals ) psoriasis vaccine Use systemic therapy psoriasis ( e.g . PUVA , systemic steroid , cyclosporin A , methotrexate , retinoids ) within four week prior Visit 2 Use UV therapy excessive UV exposure topical therapy psoriasis bland emollient within two week prior Visit 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Psoriasis</keyword>
</DOC>